ES2989669T3 - Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana - Google Patents

Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana Download PDF

Info

Publication number
ES2989669T3
ES2989669T3 ES20158066T ES20158066T ES2989669T3 ES 2989669 T3 ES2989669 T3 ES 2989669T3 ES 20158066 T ES20158066 T ES 20158066T ES 20158066 T ES20158066 T ES 20158066T ES 2989669 T3 ES2989669 T3 ES 2989669T3
Authority
ES
Spain
Prior art keywords
seq
hil
binding
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20158066T
Other languages
English (en)
Spanish (es)
Inventor
Onur Boyman
Natalia Arenas-Ramirez
Chao Zou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Application granted granted Critical
Publication of ES2989669T3 publication Critical patent/ES2989669T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES20158066T 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana Active ES2989669T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14176619 2014-07-10

Publications (1)

Publication Number Publication Date
ES2989669T3 true ES2989669T3 (es) 2024-11-27

Family

ID=51162588

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20158066T Active ES2989669T3 (es) 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
ES15759938T Active ES2779977T3 (es) 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15759938T Active ES2779977T3 (es) 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana

Country Status (9)

Country Link
US (2) US10894828B2 (enExample)
EP (2) EP3693389B1 (enExample)
JP (1) JP7209464B2 (enExample)
CN (1) CN106604932B (enExample)
AU (1) AU2015287227B2 (enExample)
CA (1) CA2954476C (enExample)
DK (1) DK3166973T3 (enExample)
ES (2) ES2989669T3 (enExample)
WO (1) WO2016005950A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1257518A1 (zh) 2016-01-11 2019-10-25 Novartis Ag 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
CN110087681A (zh) 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
WO2018156955A1 (en) * 2017-02-23 2018-08-30 City Of Hope Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd
US11274146B2 (en) 2017-03-23 2022-03-15 The Trustees Of The University Of Pennsylvania Anti-C5a antibodies and uses thereof
US11117958B2 (en) 2017-05-25 2021-09-14 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN115768483A (zh) 2020-01-13 2023-03-07 西纳福克斯股份有限公司 抗体与免疫细胞衔接器的缀合物
MX2022010034A (es) 2020-02-16 2022-12-13 Aulos Bioscience Inc Anticuerpos anti-il-2 diseñados.
PH12022552719A1 (en) * 2020-04-22 2024-02-05 Merck Sharp & Dohme Llc HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
CN116783213A (zh) * 2020-08-18 2023-09-19 苏黎世大学 Cd25偏向的抗il‐2抗体
CA3189257A1 (en) * 2020-08-18 2022-02-24 Universitat Zurich A cd25-biased anti-il-2 antibody
JP2024506022A (ja) 2021-02-08 2024-02-08 シンアフィックス ビー．ブイ． 多機能性抗体
CA3234995A1 (en) 2021-10-14 2023-04-20 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119912559B (zh) * 2025-01-22 2025-12-26 贵州中医药大学 一种新冠病毒变异株jn.1刺突s蛋白的单链抗体及其应用
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210634A (en) * 1983-12-23 1989-05-29 Hoffmann La Roche Purification of recombinant human interleukin - 2; pharmaceutical compositions
DK134487A (da) * 1986-03-17 1987-09-18 Hoffmann La Roche Monoklonalt antistof med affinitet for humant interleukin-2
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
EP1888644A1 (en) * 2005-06-01 2008-02-20 Micromet AG Anti-il2 antibodies
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CN101573139A (zh) * 2006-02-16 2009-11-04 纳森特生物制剂公司 在哺乳动物个体中改善免疫功能的方法以及预防或治疗疾病的方法
CN101045923B (zh) * 2006-03-31 2011-11-23 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
DK3339323T3 (da) * 2010-08-12 2020-01-20 Lilly Co Eli Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Also Published As

Publication number Publication date
US20210230269A1 (en) 2021-07-29
CA2954476A1 (en) 2016-01-14
WO2016005950A1 (en) 2016-01-14
AU2015287227A8 (en) 2017-02-16
EP3166973B1 (en) 2020-02-19
JP2017525343A (ja) 2017-09-07
EP3693389A1 (en) 2020-08-12
AU2015287227A1 (en) 2017-02-09
EP3166973A1 (en) 2017-05-17
US10894828B2 (en) 2021-01-19
CN106604932A (zh) 2017-04-26
DK3166973T3 (da) 2020-04-06
AU2015287227B2 (en) 2021-02-18
EP3693389B1 (en) 2024-09-04
EP3693389A9 (en) 2021-04-07
EP3693389C0 (en) 2024-09-04
JP7209464B2 (ja) 2023-01-20
US20170183403A1 (en) 2017-06-29
CA2954476C (en) 2023-09-19
CN106604932B (zh) 2024-12-10
ES2779977T3 (es) 2020-08-21

Similar Documents

Publication Publication Date Title
ES2779977T3 (es) Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
CN113166246B (zh) 一种抗体及其用途
CN111051347B (zh) Tigit抗体、其抗原结合片段及医药用途
US10081680B2 (en) Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies
ES2952132T3 (es) Nuevo anticuerpo anti-pad4
CN117120477A (zh) 针对密蛋白18a2和cd3的双特异性抗体及其应用
JP7711208B2 (ja) Ｄｌｌ３に対する結合分子及びその使用
TWI882142B (zh) 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
KR102428255B1 (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
CN112094348A (zh) 抗人Tim3抗体或其功能性片段及其应用
US20260098093A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN115210263A (zh) 抗axl抗体和组合物
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
ES2907717T3 (es) Proteínas y usos
CN115335402B (zh) 特异性抗原结合分子,其制备方法及医药用途
CN118215685A (zh) 抗gucy2c抗体及其应用
RU2837590C1 (ru) Антитела против axl и композиции
RU2837590C9 (ru) Антитела против axl и композиции
US20190194319A1 (en) Anti-ascl1 antibodies and methods of use
WO2018213680A1 (en) Diagnostic antibodies and methods of use
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40049006A (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof